|
Study
|
Study size (N)
|
Study design
|
Efficacy of therapy
|
Improvement of QOL (N; %)
|
|---|
|
Group 1
|
Group 2
|
Group 1
|
Group 2
|
Group 1
|
Group 2
|
|---|
|
Group 1
|
Group 2
|
CR
|
PR
|
SD
|
PD
|
CR
|
PR
|
SD
|
PD
|
N
|
%
|
N
|
%
|
|---|
|
Changjie H 2001 [15]
|
30
|
30
|
Cisplatin+IL-2
|
Cisplatin
|
16
|
10
|
4
|
6
|
8
|
16
|
–
|
–
|
–
|
–
|
|
Xiuzhi Y 2001 [16]
|
40
|
20
|
Cisplatin+IL-2
|
Cisplatin
|
17
|
19
|
5
|
8
|
7
|
5
|
–
|
–
|
–
|
–
|
|
Zhuo S 2004 [17]
|
32
|
30
|
Cisplatin+IL-2
|
Cisplatin
|
14
|
12
|
4
|
2
|
5
|
10
|
6
|
9
|
20
|
63
|
11
|
37
|
|
Junyan W 2005 [18]
|
48
|
34
|
Cisplatin+IL-2
|
Cisplatin
|
25
|
14
|
9
|
12
|
8
|
14
|
–
|
–
|
–
|
–
|
|
Haiying X 2009 [19]
|
35
|
28
|
Cisplatin+IL-2
|
Cisplatin
|
10
|
18
|
7
|
3
|
12
|
13
|
–
|
–
|
–
|
–
|
|
Xiaoxia H 2009 [20]
|
37
|
35
|
Cisplatin+IL-2
|
Cisplatin
|
15
|
16
|
3
|
3
|
8
|
11
|
7
|
9
|
29
|
78.3
|
19
|
54.3
|
|
Lizheng C 2009 [21]
|
46
|
40
|
Cisplatin+IL-2
|
Cisplatin
|
26
|
13
|
7
|
13
|
10
|
17
|
–
|
–
|
–
|
–
|
|
Jinguang C 2009 [22]
|
31
|
31
|
Cisplatin+IL-2
|
Cisplatin
|
12
|
17
|
2
|
7
|
13
|
11
|
–
|
–
|
–
| |
|
Junfeng W 2010 [23]
|
41
|
41
|
Cisplatin+IL-2
|
Cisplatin
|
29
|
4
|
3
|
5
|
7
|
15
|
3
|
16
|
–
|
–
|
–
|
–
|
|
Jingping Z 2010 [24]
|
63
|
61
|
Cisplatin+IL-2
|
Cisplatin
|
25
|
30
|
5
|
3
|
12
|
22
|
4
|
23
|
–
|
–
|
–
|
–
|
|
Cheng X 2010 [25]
|
41
|
41
|
Cisplatin+IL-2
|
Cisplatin
|
21
|
17
|
3
|
13
|
8
|
20
|
–
|
–
|
–
|
–
|
|
Fang S 2011 [26]
|
30
|
30
|
Cisplatin+IL-2
|
Cisplatin
|
9
|
17
|
4
|
7
|
14
|
9
|
26
|
86.7
|
24
|
80
|
|
Xueling L 2011 [27]
|
34
|
34
|
Cisplatin+IL-2
|
Cisplatin
|
19
|
11
|
4
|
8
|
10
|
16
|
–
|
–
|
–
|
–
|
|
Yan Q 2011 [28]
|
41
|
35
|
Cisplatin+IL-2
|
Cisplatin
|
12
|
24
|
3
|
2
|
6
|
12
|
4
|
13
|
–
|
–
|
–
|
–
|
|
Li J 2013 [29]
|
38
|
35
|
Cisplatin+IL-2
|
Cisplatin
|
12
|
13
|
13
|
4
|
11
|
20
|
27
|
71.1
|
17
|
48.6
|
|
Lijie H 2014 [30]
|
30
|
30
|
Cisplatin+IL-2
|
Cisplatin
|
12
|
13
|
5
|
7
|
10
|
13
|
26
|
86.7
|
19
|
63.3
|
|
Miao H 2016 [31]
|
31
|
30
|
Cisplatin+IL-2
|
Cisplatin
|
11
|
15
|
5
|
7
|
10
|
13
|
–
|
–
|
–
|
–
|
|
Baohua Y 2017 [32]
|
33
|
33
|
Cisplatin+IL-2
|
Cisplatin
|
11
|
18
|
3
|
1
|
8
|
14
|
6
|
5
|
–
|
–
|
–
|
–
|
- N, cases, IL-2 interleukin-2; Group 1 = IL-2 combined+cisplatin; Group 2 = cisplatin alone, CR complete response, PR partial response, SD stable disease, PD progressive disease, QOL quality of life
